Lucid Diagnostics Inc. (LUCD) NASDAQ

1.11

+0.01(+0.91%)

Updated at December 24 01:00PM

Currency In USD

Lucid Diagnostics Inc.

Address

One Grand Central Place

New York City, NY 10165

United States of America

Phone

212 949 4319

Sector

Healthcare

Industry

Medical - Devices

Employees

72

First IPO Date

October 14, 2021

Key Executives

NameTitlePayYear Born
Lishan AklogChairman & Chief Executive Officer300,0001966
Amitabh ChakCo-Founder & Strategic Advisor14,535N/A
Sanford D. MarkowitzCo-Founder & Strategic Advisor14,535N/A
Helen MoinovaCo-Founder & Strategic Advisor14,535N/A
Dennis McGrathChief Financial Officer225,0001957
Michael Adam GordonGeneral Counsel & Secretary250,0001974
Shaun O'NeillPresident & Chief Operating Officer300,0001982
Brian J. deGuzmanChief Technology & Compliance Officer01965
Joseph WillisCo-founder & Strategic Advisor0N/A
Suman VermaChief Scientific Officer0N/A

Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.